* Calithera Biosciences Inc CALA.OQ CALA.O is expected
to show
no change in quarterly revenue when it reports results on March
18 (estimated).
* Refinitiv's mean analyst estimate for Calithera
Biosciences Inc
is for a loss of 24 cents per share. For the same quarter last
year, the company reported a loss of 32 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Calithera
Biosciences Inc is $3, above its last closing price of $0.52.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2021 -0.22 -0.23 -0.15 Beat 34.2
Jun. 30 2021 -0.24 -0.24 -0.19 Beat 20.9
Mar. 31 2021 -0.27 -0.28 -0.28 Met -1.4
Dec. 31 2020 -0.33 -0.32 -0.32 Met 1.2
Sep. -0.31 -0.31 -0.32 Missed -3.1
30 2020
Jun. 30 2020 -0.33 -0.33 -0.29 Beat 13.3
Mar. 31 2020 -0.36 -0.36 -0.38 Missed -5.8
Dec. 31 2019 -0.39 -0.37 -0.39 Missed -4.7
This summary was machine generated March 18 at 20:56 GMT. All
figures in US dollars unless otherwise stated